Journal Club E61: Finerenone Beyond Diabetes: The 2026 CKD Evidence Reset

from AZense Journal Club · host Azense Medical Education

A 2026 wave of trials moves finerenone from a diabetic-kidney drug toward a broad cardiorenal agent. FIND-CKD is the first Phase 3 win in non-diabetic CKD, but the glomerular subgroup, the INFINITY pooled analysis, and CONFIDENCE are exploratory or surrogate-based, and hyperkalemia remains the constant caveat.

Episode metadata supplied by the publisher feed · Published Jul 6, 2026

Embed this episode

Attribution link and audio player

Ready to play

Journal Club E61: Finerenone Beyond Diabetes: The 2026 CKD Evidence Reset

0:00 10:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AZense Journal Club?

This episode is 10 minutes long.

When was this AZense Journal Club episode published?

This episode was published on July 6, 2026.

Can I download this AZense Journal Club episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!